The presentations at ASCO GU signal a move toward more personalized, potent, and sequence-specific treatment strategies for genitourinary malignancies.
CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.
The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, discussing three abstracts, “Belzutifan + lenvatinib versus cabozantinib for ...
Overall, day two of ASCO GU emphasized that advances in therapy must go hand-in-hand with patient-centered research. These ...
The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart, discussing two abstracts: “Neoadjuvant and adjuvant EV + pembrolizumab ...
Dr Parikh explained that KEYNOTE-B15 (NCT04700124) is evaluating the role of perioperative enfortumab vedotin (Padcev), an ...
The first half of this year has been riddled with market volatility and geopolitical tension. But 2025’s American Society of Clinical Oncology conference largely isn’t reflecting that turmoil. In fact ...
Plus Therapeutics will present ReSPECT-LM trial results and host a symposium on leptomeningeal metastases at the SNO/ASCO conference. Announcement of the oral presentation of ReSPECT-LM clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results